Dubbed Intellia Therapeutics, the new company has come up with a $15 million bankroll in a Series A provided by the venture group and the Big Pharma outfit, which is intrigued by the potential this gene editing technology could play in two of the hottest fields in oncology.

…read more

Source: Novartis joins Atlas in launching a CRISPR Cas biotech with a $15M bankroll


0 No comments